

Nouveau Biosciences and CanceRx Execute Memorandum of Understanding (MOU) to Advance NBS-002, into Clinical Development

\$10 Million Strategic Investment Supports Regulatory and Clinical Advancement of Second Pipeline Asset

[New York, NY – February 26, 2026] – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, today announced that it has executed a Memorandum of Understanding (MOU) with CanceRx, a purpose-driven funding and development platform focused on advancing innovative oncology treatments through long-duration capital and strategic partnerships.

Under the MOU, Nouveau Biosciences and CanceRx intend to collaborate on the clinical and regulatory advancement of NBS-M002, Nouveau’s second pipeline asset derived from its proprietary nanomedicine platform. The proposed \$10 million strategic investment is intended to support the progression of NBS-M002 through key clinical and regulatory milestones, positioning the program for potential licensing and eventual commercialization.

NBS-M002 has demonstrated marked preclinical activity across multiple poor-prognosis malignancies, including acute myeloid leukemia (AML), cutaneous T-cell lymphoma (CTCL), and non-small cell lung cancer (NSCLC).

CanceRx employs a differentiated development model that emphasizes long-horizon capital and active partnership to advance promising oncology assets through key clinical and regulatory milestones. This approach is designed to align with pharmaceutical industry preferences for acquiring well-validated, de-risked programs for late-stage development and market launch.

“CanceRx is emerging as one of the leaders in funding the next generation of breakthrough cancer therapies,” said Owen A. O’Connor, M.D., Ph.D., Founder, Chief Executive Officer, and Chairman of Nouveau Biosciences. “Their model is distinctive, but more importantly, their team is deeply committed to enabling science-driven innovation. This philosophy aligns closely with Nouveau’s proprietary Nouveau Nexus™ platform and our focus on building durable, long-term value through clinically meaningful drug development.”

Nouveau Biosciences has developed a proprietary polymer-based nanoparticle platform designed to enhance drug tolerability, targeting, and therapeutic performance. The technology enables the encapsulation and delivery of a wide range of anti-cancer agents, including combinations as demonstrated by the Nouveau Nexus™ technology. NBS-M002 builds on this validated chemistry and biology, reinforcing the company’s ability to generate a pipeline of IP-protected, clinically relevant nanotherapeutic drug candidates.

“Nouveau Biosciences represents exactly the kind of innovative, ‘outside-the-box’ oncology company we seek to partner with,” said Clifford S. Gibbons, JD, Executive Director of CanceRx Foundation, Inc. and Managing Director of CanceRx, LLC. “The Nouveau Nexus™ platform and its novel, IP-protected nanomedicines have the potential to meaningfully transform cancer drug development. We are excited to work with this exceptionally talented team.”

Further details regarding the proposed collaboration will be announced upon the execution of definitive agreements.

About Nouveau Biosciences

Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology, the *Nouveau Nexus™*, that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company’s lead programs are clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.

About CanceRx

CanceRx is a nonprofit and investment platform designed to support the development of promising cancer drugs through long-duration funding, clinical guidance, and FDA submission support. The organization partners with scientific innovators to bring life-changing oncology therapies to patients and works closely with pharmaceutical companies to license and scale validated assets. Learn more at <https://cancerx.us>.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the companies’ future plans, development and licensing of cancer therapeutics, and the potential success of the collaboration. All statements other than statements of historical fact are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. Nouveau Biosciences undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Media Contact

Petrina Whyte

media@nouveaubiosciences.com